Julia Wawerska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Julia Wawerska has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Bartosz Okliński
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Lublin, Poland
9 shared publications - Jakub Skrzypek
Medical University of Lublin, Poland al. Racławickie 1, 20-059 Lublin, Poland
9 shared publications - Kamila Zioło
1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland
9 shared publications - Karol Szyprowski
Faculty of Medicine, Medical University of Lublin, Aleje Racławickie 1, 20-059 Lublin, Poland
9 shared publications - Maciej Kisielewski
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin
9 shared publications - Mateusz Zugaj
Stefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin Al. Kraśnicka 100, 20-718 Lublin, Poland
9 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 74683
Treatment-Resistant Depression: A Literature Review of Innovative and Emerging Treatment Strategies
Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturbances, including changes in cognitive skills, appetite, and sleep patterns. Although many treatment strategies are well-established and available, not all patients achieve satisfactory improvement. Treatment-resistant depression (TRD), often defined as insufficient response to at least two antidepressant trials of proper dose and duration, represents a major therapeutic challenge. This review aims to present and assess emerging treatment strategies for TRD, focusing on their mechanisms, effectiveness and safety. Brief description of the state of knowledge: Recent advances in the understanding of depression pathophysiology have initiated the development of new therapeutic approaches targeting various systems thought to be involved in mood regulation. Glutamatergic modulators, such as ketamine and esketamine, have demonstrated prompt antidepressant effects, particularly in patients with severe or refractory symptoms. Neuromodulatory techniques, including repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT), remain important treatment options with growing research interest. Simultaneously, heightened attention has been directed toward psychedelic-assisted therapies, especially psilocybin, which may produce sustained antidepressant effects through modulation of various neural networks. Additionally, invasive interventions such as vagus nerve stimulation (VNS) and deep brain stimulation (DBS) are being studied for resistant cases, although their use remains limited. Summary: Emerging therapies for TRD offer promising alternatives to conventional treatment strategies, particularly for patients not responding to routine interventions. Further research is crucial for the optimization of therapeutic outcomes and integration of those novel approaches into clinical practice.
- 17 September 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 73, 74683
Open AccessTreatment-Resistant Depression: A Literature Review of Innovative and Emerging Treatment Strategies
Introduction and objective: Major depressive disorder (MDD) is a heterogeneous psychiatric condition characterized by affective, cognitive and somatic symptoms that considerably impair daily functioning. It is defined clinically by prolonged low mood, diminished interest or pleasure, and a range of associated disturbances, including changes in cognitive skills, appetite, and sleep patterns. Although many treatment strategies are well-established and available, not all patients achieve satisfactory improvement. Treatment-resistant depression (TRD), often defined as insufficient response to at least two antidepressant trials of proper dose and duration, represents a major therapeutic challenge. This review aims to present and assess emerging treatment strategies for TRD, focusing on their mechanisms, effectiveness and safety. Brief description of the state of knowledge: Recent advances in the understanding of depression pathophysiology have initiated the development of new therapeutic approaches targeting various systems thought to be involved in mood regulation. Glutamatergic modulators, such as ketamine and esketamine, have demonstrated prompt antidepressant effects, particularly in patients with severe or refractory symptoms. Neuromodulatory techniques, including repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT), remain important treatment options with growing research interest. Simultaneously, heightened attention has been directed toward psychedelic-assisted therapies, especially psilocybin, which may produce sustained antidepressant effects through modulation of various neural networks. Additionally, invasive interventions such as vagus nerve stimulation (VNS) and deep brain stimulation (DBS) are being studied for resistant cases, although their use remains limited. Summary: Emerging therapies for TRD offer promising alternatives to conventional treatment strategies, particularly for patients not responding to routine interventions. Further research is crucial for the optimization of therapeutic outcomes and integration of those novel approaches into clinical practice.
- Open Access
- 11 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 62, 73254
Therapeutic Myostatin Inhibitors in Sarcopenia – A Review of Their Effects on Muscle Mass, Strength, and Function
Background. Sarcopenia is an age-related syndrome characterized by progressive loss of skeletal muscle mass, strength, and physical performance, leading to increased risks of disability, falls, hospitalization, and mortality. Myostatin, a negative regulator of muscle growth, has emerged as a potential therapeutic target in sarcopenia. Aim. The aim of this review was to evaluate the current evidence regarding the use of myostatin inhibitors in sarcopenia, with particular emphasis on their effects on muscle mass, strength, and physical function. Material and methods. A narrative review of the literature was conducted, including experimental studies, randomized controlled trials, systematic reviews, and meta-analyses investigating myostatin inhibition in sarcopenia and related muscle-wasting conditions. Results. Available evidence indicates that myostatin inhibitors increase lean body mass and promote skeletal muscle hypertrophy. Clinical studies, particularly those involving bimagrumab, demonstrated significant gains in muscle volume and lean mass. However, improvements in muscle strength and physical performance were generally limited and not always proportional to increases in muscle mass. Current evidence is constrained by heterogeneous study populations and short follow-up periods. Conclusions. Myostatin inhibitors may represent a useful pharmacological strategy for increasing muscle mass in sarcopenia. Nevertheless, their effects on functional outcomes remain uncertain. Further studies are needed to assess long-term clinical benefits and the effectiveness of combining pharmacological treatment with exercise and nutritional interventions.
- 11 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 62, 73254
Open AccessTherapeutic Myostatin Inhibitors in Sarcopenia – A Review of Their Effects on Muscle Mass, Strength, and Function
Background. Sarcopenia is an age-related syndrome characterized by progressive loss of skeletal muscle mass, strength, and physical performance, leading to increased risks of disability, falls, hospitalization, and mortality. Myostatin, a negative regulator of muscle growth, has emerged as a potential therapeutic target in sarcopenia. Aim. The aim of this review was to evaluate the current evidence regarding the use of myostatin inhibitors in sarcopenia, with particular emphasis on their effects on muscle mass, strength, and physical function. Material and methods. A narrative review of the literature was conducted, including experimental studies, randomized controlled trials, systematic reviews, and meta-analyses investigating myostatin inhibition in sarcopenia and related muscle-wasting conditions. Results. Available evidence indicates that myostatin inhibitors increase lean body mass and promote skeletal muscle hypertrophy. Clinical studies, particularly those involving bimagrumab, demonstrated significant gains in muscle volume and lean mass. However, improvements in muscle strength and physical performance were generally limited and not always proportional to increases in muscle mass. Current evidence is constrained by heterogeneous study populations and short follow-up periods. Conclusions. Myostatin inhibitors may represent a useful pharmacological strategy for increasing muscle mass in sarcopenia. Nevertheless, their effects on functional outcomes remain uncertain. Further studies are needed to assess long-term clinical benefits and the effectiveness of combining pharmacological treatment with exercise and nutritional interventions.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
THE NEUROBIOLOGICAL AND IMMUNOLOGICAL BASIS OF THE CO-OCCURRENCE OF ENDOMETRIOSIS WITH DEPRESSION AND ANXIETY: A SYSTEMATIC REVIEW
Introduction: Endometriosis is a chronic, oestrogen-dependent inflammatory condition affecting approximately 10% of women of reproductive age worldwide. In addition to its well-documented gynaecological symptoms, endometriosis is increasingly associated with psychiatric disorders, particularly depression and anxiety disorders. The neurobiological and immunological mechanisms underpinning this comorbidity remain poorly understood. Objective: This systematic review aims to synthesise current data on the neurobiological, neuroendocrine and immunological mechanisms linking endometriosis to depression and anxiety disorders, taking into account additional psychiatric symptoms such as sleep disorders, post-traumatic stress disorder (PTSD) and sexual dysfunction. Methods: A systematic search of the PubMed/MEDLINE database was conducted to identify articles published between January 2008 and March 2026, using predefined search terms relating to endometriosis, mental health, neuroinflammation and immune dysregulation. Study selection was carried out in accordance with the PRISMA 2020 guidelines. Studies analysing the association between endometriosis and psychiatric outcomes, or investigating the underlying biological mechanisms, were included. Results: Thirty studies met the inclusion criteria. The data consistently indicate elevated rates of depression (prevalence 9.8-98.5 per cent) and anxiety (11.5-87.5 per cent) in women with endometriosis compared with the general population. Key mechanisms identified include: dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis; systemic and central neuroinflammation mediated by pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha), oestrogen-induced neurotransmitter imbalances, central sensitisation, oxidative stress and gut-brain axis dysfunction. Conclusions: The relationship between endometriosis and psychiatric disorders is bidirectional and mediated by combined neuroendocrine-immunological pathways. These findings highlight the need for integrated, multidisciplinary management strategies that take into account both the somatic and psychological dimensions of endometriosis.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessTHE NEUROBIOLOGICAL AND IMMUNOLOGICAL BASIS OF THE CO-OCCURRENCE OF ENDOMETRIOSIS WITH DEPRESSION AND ANXIETY: A SYSTEMATIC REVIEW
Introduction: Endometriosis is a chronic, oestrogen-dependent inflammatory condition affecting approximately 10% of women of reproductive age worldwide. In addition to its well-documented gynaecological symptoms, endometriosis is increasingly associated with psychiatric disorders, particularly depression and anxiety disorders. The neurobiological and immunological mechanisms underpinning this comorbidity remain poorly understood. Objective: This systematic review aims to synthesise current data on the neurobiological, neuroendocrine and immunological mechanisms linking endometriosis to depression and anxiety disorders, taking into account additional psychiatric symptoms such as sleep disorders, post-traumatic stress disorder (PTSD) and sexual dysfunction. Methods: A systematic search of the PubMed/MEDLINE database was conducted to identify articles published between January 2008 and March 2026, using predefined search terms relating to endometriosis, mental health, neuroinflammation and immune dysregulation. Study selection was carried out in accordance with the PRISMA 2020 guidelines. Studies analysing the association between endometriosis and psychiatric outcomes, or investigating the underlying biological mechanisms, were included. Results: Thirty studies met the inclusion criteria. The data consistently indicate elevated rates of depression (prevalence 9.8-98.5 per cent) and anxiety (11.5-87.5 per cent) in women with endometriosis compared with the general population. Key mechanisms identified include: dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis; systemic and central neuroinflammation mediated by pro-inflammatory cytokines (IL-1beta, IL-6, TNF-alpha), oestrogen-induced neurotransmitter imbalances, central sensitisation, oxidative stress and gut-brain axis dysfunction. Conclusions: The relationship between endometriosis and psychiatric disorders is bidirectional and mediated by combined neuroendocrine-immunological pathways. These findings highlight the need for integrated, multidisciplinary management strategies that take into account both the somatic and psychological dimensions of endometriosis.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
ANTI-INFLAMMATORY DIETARY PATTERNS IN ENDOMETRIOSIS: MECHANISMS, CLINICAL EVIDENCE, AND PERSPECTIVES FOR FUTURE RESEARCH
Purpose: The aim of this article was to provide an in-depth review of the current literature and research on the role of anti-inflammatory dietary patterns in the treatment of endometriosis. Methodology: A thorough and extensive review of the literature was conducted using various scientific databases, such as PubMed, Google Scholar and Scopus. During the selection process, particular attention was paid to clinical trials, systematic reviews and meta-analyses concerning dietary patterns, specific nutrients and bioactive anti-inflammatory compounds in relation to the risk, severity of symptoms and progression of endometriosis. Findings: Evidence indicates that anti-inflammatory diets may help manage endometriosis symptoms. However, the few available clinical studies are varied and often low in quality. There is also a lack of long-term randomized controlled trials with standardized protocols and biomarker endpoints, making it difficult to confirm causality or create clinical guidelines. Conclusion: Anti-inflammatory diets may help reduce endometriosis symptoms by lowering inflammation, affecting oestrogen metabolism, and regulating the gut microbiome—factors central to disease progression. While observational studies and small trials suggest benefits from diets rich in whole foods and low in red meat and trans fats, more advanced clinical trials are needed. The authors highlight the importance of further research using biomarkers and personalized nutrition to create evidence-based dietary guidelines. Future studies should assess diet alongside inflammation, hormone, and microbiome profiles to support tailored nutritional strategies for endometriosis treatment.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessANTI-INFLAMMATORY DIETARY PATTERNS IN ENDOMETRIOSIS: MECHANISMS, CLINICAL EVIDENCE, AND PERSPECTIVES FOR FUTURE RESEARCH
Purpose: The aim of this article was to provide an in-depth review of the current literature and research on the role of anti-inflammatory dietary patterns in the treatment of endometriosis. Methodology: A thorough and extensive review of the literature was conducted using various scientific databases, such as PubMed, Google Scholar and Scopus. During the selection process, particular attention was paid to clinical trials, systematic reviews and meta-analyses concerning dietary patterns, specific nutrients and bioactive anti-inflammatory compounds in relation to the risk, severity of symptoms and progression of endometriosis. Findings: Evidence indicates that anti-inflammatory diets may help manage endometriosis symptoms. However, the few available clinical studies are varied and often low in quality. There is also a lack of long-term randomized controlled trials with standardized protocols and biomarker endpoints, making it difficult to confirm causality or create clinical guidelines. Conclusion: Anti-inflammatory diets may help reduce endometriosis symptoms by lowering inflammation, affecting oestrogen metabolism, and regulating the gut microbiome—factors central to disease progression. While observational studies and small trials suggest benefits from diets rich in whole foods and low in red meat and trans fats, more advanced clinical trials are needed. The authors highlight the importance of further research using biomarkers and personalized nutrition to create evidence-based dietary guidelines. Future studies should assess diet alongside inflammation, hormone, and microbiome profiles to support tailored nutritional strategies for endometriosis treatment.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
DYSMENORRHEA: PATHOPHYSIOLOGY AND CONTEMPORARY PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT APPROACHES
Purpose: This paper aims to analyze current scientific evidence regarding the pathophysiology of primary dysmenorrhea and to evaluate the effectiveness of both pharmacological and non-pharmacological treatment strategies used to reduce menstrual pain and improve the quality of life of affected women. Methodology: A comprehensive literature review was conducted using scientific databases such as PubMed and Google Scholar. The search included keywords such as “primary dysmenorrhea”, “menstrual pain”, “NSAIDs”, “hormonal therapy”, “non-pharmacological treatment”, “TENS”, “thermotherapy”, and “physical activity”. Particular attention was given to systematic reviews, meta-analyses, randomized controlled trials (RCTs), and clinical recommendations from international medical organizations. Publications analyzing both pharmacological and non-pharmacological therapeutic approaches were included, with emphasis on studies assessing treatment effectiveness, safety, and their impact on quality of life. Findings: Primary dysmenorrhea is a common gynecological condition significantly affecting the physical, psychological, and social functioning of women. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first-line pharmacological treatment due to their ability to reduce prostaglandin production and alleviate menstrual pain. Hormonal therapy is an effective alternative, particularly in women not planning pregnancy. In addition, non-pharmacological interventions such as thermotherapy, transcutaneous electrical nerve stimulation (TENS), physical activity, physiotherapy, and complementary therapies may contribute to pain reduction and improved well-being. However, the quality of evidence supporting some non-pharmacological methods remains limited. Conclusions: Effective management of primary dysmenorrhea requires an individualized and comprehensive therapeutic approach that integrates both pharmacological and non-pharmacological strategies. Increasing awareness of available treatment options and promoting multidisciplinary care may significantly improve patient outcomes and quality of life.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessDYSMENORRHEA: PATHOPHYSIOLOGY AND CONTEMPORARY PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT APPROACHES
Purpose: This paper aims to analyze current scientific evidence regarding the pathophysiology of primary dysmenorrhea and to evaluate the effectiveness of both pharmacological and non-pharmacological treatment strategies used to reduce menstrual pain and improve the quality of life of affected women. Methodology: A comprehensive literature review was conducted using scientific databases such as PubMed and Google Scholar. The search included keywords such as “primary dysmenorrhea”, “menstrual pain”, “NSAIDs”, “hormonal therapy”, “non-pharmacological treatment”, “TENS”, “thermotherapy”, and “physical activity”. Particular attention was given to systematic reviews, meta-analyses, randomized controlled trials (RCTs), and clinical recommendations from international medical organizations. Publications analyzing both pharmacological and non-pharmacological therapeutic approaches were included, with emphasis on studies assessing treatment effectiveness, safety, and their impact on quality of life. Findings: Primary dysmenorrhea is a common gynecological condition significantly affecting the physical, psychological, and social functioning of women. Nonsteroidal anti-inflammatory drugs (NSAIDs) remain the first-line pharmacological treatment due to their ability to reduce prostaglandin production and alleviate menstrual pain. Hormonal therapy is an effective alternative, particularly in women not planning pregnancy. In addition, non-pharmacological interventions such as thermotherapy, transcutaneous electrical nerve stimulation (TENS), physical activity, physiotherapy, and complementary therapies may contribute to pain reduction and improved well-being. However, the quality of evidence supporting some non-pharmacological methods remains limited. Conclusions: Effective management of primary dysmenorrhea requires an individualized and comprehensive therapeutic approach that integrates both pharmacological and non-pharmacological strategies. Increasing awareness of available treatment options and promoting multidisciplinary care may significantly improve patient outcomes and quality of life.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
ENDOCARDIAL INVOLVEMENT IN SYSTEMIC AUTOIMMUNE DISEASES: PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS, AND MANAGEMENT
Purpose: The manuscript aims to highlight the clinical significance of Libman-Sacks endocarditis (LSE) in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). It emphasizes the importance of early diagnosis and multidisciplinary management to prevent severe cardiac complications and improve patient outcomes. Methodology: A comprehensive review of recent literature and case studies was conducted, focusing on the pathogenesis, clinical presentation, diagnostic approaches, and management strategies for LSE in SLE and APS patients. The article synthesizes evidence from published research, including echocardiographic findings, laboratory markers, and therapeutic interventions Findings: LSE is frequently underdiagnosed due to its subtle clinical manifestations. Echocardiography remains the gold standard for detection, revealing characteristic vegetations on heart valves. The manuscript identifies a strong association between LSE and thromboembolic events in SLE/APS patients. Multidisciplinary collaboration among cardiologists, rheumatologists, hematologists, and cardiac surgeons is crucial for optimal management. Anticoagulation and immunosuppressive therapy are central to treatment, with surgical intervention reserved for severe cases. Conclusions: Early recognition and coordinated care are essential to reduce morbidity and mortality associated with LSE in SLE and APS. The article advocates for routine cardiac screening in high-risk patients and underscores the need for further research to refine diagnostic and therapeutic protocols.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessENDOCARDIAL INVOLVEMENT IN SYSTEMIC AUTOIMMUNE DISEASES: PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS, AND MANAGEMENT
Purpose: The manuscript aims to highlight the clinical significance of Libman-Sacks endocarditis (LSE) in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). It emphasizes the importance of early diagnosis and multidisciplinary management to prevent severe cardiac complications and improve patient outcomes. Methodology: A comprehensive review of recent literature and case studies was conducted, focusing on the pathogenesis, clinical presentation, diagnostic approaches, and management strategies for LSE in SLE and APS patients. The article synthesizes evidence from published research, including echocardiographic findings, laboratory markers, and therapeutic interventions Findings: LSE is frequently underdiagnosed due to its subtle clinical manifestations. Echocardiography remains the gold standard for detection, revealing characteristic vegetations on heart valves. The manuscript identifies a strong association between LSE and thromboembolic events in SLE/APS patients. Multidisciplinary collaboration among cardiologists, rheumatologists, hematologists, and cardiac surgeons is crucial for optimal management. Anticoagulation and immunosuppressive therapy are central to treatment, with surgical intervention reserved for severe cases. Conclusions: Early recognition and coordinated care are essential to reduce morbidity and mortality associated with LSE in SLE and APS. The article advocates for routine cardiac screening in high-risk patients and underscores the need for further research to refine diagnostic and therapeutic protocols.
- Open Access
- 27 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 60
Preoperative Strategies for the Prevention of Surgical Site Infections in Athletes: A Review
Surgical site infections (SSIs) remain among the most common healthcare-associated infections, contributing to increased morbidity, prolonged hospitalization, higher healthcare costs, and delayed recovery. This review evaluates current evidence regarding preoperative strategies for SSI prevention, with particular emphasis on measures relevant to athletic and physically active populations undergoing surgical procedures. Key interventions examined include preoperative body washing, skin antisepsis, hair removal practices, and perioperative glycemic control. Available evidence suggests that while preoperative bathing, including chlorhexidine-based cleansing, improves skin hygiene, its direct effect on reducing SSI rates remains uncertain. In contrast, alcohol-based chlorhexidine skin antisepsis demonstrates consistent superiority over povidone-iodine in lowering microbial burden and reducing SSI incidence. Hair removal, when necessary, should be performed using clippers immediately before surgery, as shaving is associated with increased infection risk. Additionally, maintaining perioperative blood glucose levels below 180 mg/dL appears essential for minimizing postoperative infections. A multimodal, evidence-based approach integrating these preventive measures offers the greatest potential for reducing SSI risk and improving surgical outcomes.
- 27 June 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 60
Open AccessPreoperative Strategies for the Prevention of Surgical Site Infections in Athletes: A Review
Surgical site infections (SSIs) remain among the most common healthcare-associated infections, contributing to increased morbidity, prolonged hospitalization, higher healthcare costs, and delayed recovery. This review evaluates current evidence regarding preoperative strategies for SSI prevention, with particular emphasis on measures relevant to athletic and physically active populations undergoing surgical procedures. Key interventions examined include preoperative body washing, skin antisepsis, hair removal practices, and perioperative glycemic control. Available evidence suggests that while preoperative bathing, including chlorhexidine-based cleansing, improves skin hygiene, its direct effect on reducing SSI rates remains uncertain. In contrast, alcohol-based chlorhexidine skin antisepsis demonstrates consistent superiority over povidone-iodine in lowering microbial burden and reducing SSI incidence. Hair removal, when necessary, should be performed using clippers immediately before surgery, as shaving is associated with increased infection risk. Additionally, maintaining perioperative blood glucose levels below 180 mg/dL appears essential for minimizing postoperative infections. A multimodal, evidence-based approach integrating these preventive measures offers the greatest potential for reducing SSI risk and improving surgical outcomes.
- Open Access
- 17 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
NEUROIMMUNOLOGICAL AND METABOLIC CORRELATION: A MULTIDIMENSIONAL REVIEW OF THE LINKS BETWEEN OBESITY AND ANXIETY DISORDERS
Contemporary clinical medicine faces two global health crises: obesity and anxiety disorders. Although historically treated as independent entities, contemporary epidemiology points to a clear correlation between them – the risk of anxiety disorders in obese individuals is significantly higher. The aim of this systematic review of the literature is to provide a comprehensive, multi-level analysis of the mechanisms linking excess body weight to anxiety disorders. The study hypothesises the existence of a "metabolic-anxiety vicious circle" mediated by chronic inflammation, hypothalamic-pituitary-adrenal axis dysfunction, and gut-brain axis disorders. An extensive review was conducted in the PubMed, Scopus, Web of Science and Google Scholar databases, covering publications from 2000 to 2025. The selection included cohort studies (e.g., NEMESIS-2, LifeLines), meta-analyses, and translational studies. Analysis of the scientific evidence allows us to identify four key pathophysiological pillars. Firstly, visceral obesity generates chronic low-grade inflammation, which induces neuroinflammation in limbic structures through the blood-brain barrier. Secondly, chronic anxiety leads to dysregulation of the hypothalamic-pituitary-adrenal axis and hypercortisolemia, causing visceral obesity. Thirdly, genetic variants have pleiotropic effects. Fourthly, intestinal dysbiosis is a new key mediator in the communication between metabolism and the psyche. Obesity and anxiety are not coincidental co-occurring phenomena, but are manifestations of a common dysregulation of the body's homeostasis. This implies the need to change existing treatment patterns to an integrated model that combines somatic treatment with psychotherapeutic treatment.
- 17 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessNEUROIMMUNOLOGICAL AND METABOLIC CORRELATION: A MULTIDIMENSIONAL REVIEW OF THE LINKS BETWEEN OBESITY AND ANXIETY DISORDERS
Contemporary clinical medicine faces two global health crises: obesity and anxiety disorders. Although historically treated as independent entities, contemporary epidemiology points to a clear correlation between them – the risk of anxiety disorders in obese individuals is significantly higher. The aim of this systematic review of the literature is to provide a comprehensive, multi-level analysis of the mechanisms linking excess body weight to anxiety disorders. The study hypothesises the existence of a "metabolic-anxiety vicious circle" mediated by chronic inflammation, hypothalamic-pituitary-adrenal axis dysfunction, and gut-brain axis disorders. An extensive review was conducted in the PubMed, Scopus, Web of Science and Google Scholar databases, covering publications from 2000 to 2025. The selection included cohort studies (e.g., NEMESIS-2, LifeLines), meta-analyses, and translational studies. Analysis of the scientific evidence allows us to identify four key pathophysiological pillars. Firstly, visceral obesity generates chronic low-grade inflammation, which induces neuroinflammation in limbic structures through the blood-brain barrier. Secondly, chronic anxiety leads to dysregulation of the hypothalamic-pituitary-adrenal axis and hypercortisolemia, causing visceral obesity. Thirdly, genetic variants have pleiotropic effects. Fourthly, intestinal dysbiosis is a new key mediator in the communication between metabolism and the psyche. Obesity and anxiety are not coincidental co-occurring phenomena, but are manifestations of a common dysregulation of the body's homeostasis. This implies the need to change existing treatment patterns to an integrated model that combines somatic treatment with psychotherapeutic treatment.
- Open Access
- 16 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 90
Post-Traumatic Stress Disorder (PTSD) - Risk Factors, Treatment and Prevention - A Literature Review
Introduction and objective. Post-traumatic stress disorder is a mental disturbance that is a reaction to an extremely stressful event (trauma) that exceeds a person's ability to cope and adapt. Such events include acts of war, disasters, natural disasters, traffic accidents, being a victim of assault, rape, harassment, abduction, torture, imprisonment in a concentration camp, severe, difficult experiences after taking psychoactive substances, receiving a diagnosis of a life-threatening illness. Typical PTSD symptoms include anxiety, exhaustion, feelings of helplessness, recurring, violent involuntary memories of the traumatic event, flashbacks, hallucinations or nightmares related to the trauma, and avoidant behaviour in situations associated with the trauma. Treatment of PTSD, depending on the severity and persistence of symptoms, may include psychotherapy and pharmacotherapy. The aim of this study is to systematise information on this condition and raise awareness of this issue among healthcare professionals and patients.
- 16 April 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Journal of Education, Health and Sport
- Vol. 90
Open AccessPost-Traumatic Stress Disorder (PTSD) - Risk Factors, Treatment and Prevention - A Literature Review
Introduction and objective. Post-traumatic stress disorder is a mental disturbance that is a reaction to an extremely stressful event (trauma) that exceeds a person's ability to cope and adapt. Such events include acts of war, disasters, natural disasters, traffic accidents, being a victim of assault, rape, harassment, abduction, torture, imprisonment in a concentration camp, severe, difficult experiences after taking psychoactive substances, receiving a diagnosis of a life-threatening illness. Typical PTSD symptoms include anxiety, exhaustion, feelings of helplessness, recurring, violent involuntary memories of the traumatic event, flashbacks, hallucinations or nightmares related to the trauma, and avoidant behaviour in situations associated with the trauma. Treatment of PTSD, depending on the severity and persistence of symptoms, may include psychotherapy and pharmacotherapy. The aim of this study is to systematise information on this condition and raise awareness of this issue among healthcare professionals and patients.
- Open Access
- 27 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
RIMEGEPANT AS A NOVEL THERAPEUTIC OPTION FOR MIGRAINE: A SYSTEMATIC REVIEW OF SAFETY AND TOLERABILITY
Objective. The aim of this paper is to analyze and evaluate currently available data and studies on the safety and tolerability of rimegepant in the treatment of migraine. Methodology. This literature review was based on articles from 2019–2026 available on PubMed and Google Scholar, including randomized controlled trials, open-label studies, and meta-analyses. Findings. Adverse reactions to rimegepant observed in clinical trials are largely mild or moderate. Serious adverse reactions and those leading to treatment discontinuation are rare and often considered unrelated to the drug. The most frequently reported adverse events in the databases were related to “general disorders and administration site conditions”. Rimegepant is safe for patients with high cardiovascular risk and no hepatotoxicity associated with this drug is observed. Compared to other available therapies, rimegepant also ranks highly in terms of both efficacy and safety. Conclusion. Rimegepant is a safe and well-tolerated oral medication for both acute and preventative migraine treatment. It is also a good alternative to other poorly tolerated or contraindicated migraine drugs.
- 27 March 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (1(49))
Open AccessRIMEGEPANT AS A NOVEL THERAPEUTIC OPTION FOR MIGRAINE: A SYSTEMATIC REVIEW OF SAFETY AND TOLERABILITY
Objective. The aim of this paper is to analyze and evaluate currently available data and studies on the safety and tolerability of rimegepant in the treatment of migraine. Methodology. This literature review was based on articles from 2019–2026 available on PubMed and Google Scholar, including randomized controlled trials, open-label studies, and meta-analyses. Findings. Adverse reactions to rimegepant observed in clinical trials are largely mild or moderate. Serious adverse reactions and those leading to treatment discontinuation are rare and often considered unrelated to the drug. The most frequently reported adverse events in the databases were related to “general disorders and administration site conditions”. Rimegepant is safe for patients with high cardiovascular risk and no hepatotoxicity associated with this drug is observed. Compared to other available therapies, rimegepant also ranks highly in terms of both efficacy and safety. Conclusion. Rimegepant is a safe and well-tolerated oral medication for both acute and preventative migraine treatment. It is also a good alternative to other poorly tolerated or contraindicated migraine drugs.